Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immunic, Inc. - Common Stock (NQ: IMUX )

1.149 +0.029 (+2.60%)
Streaming Delayed Price Updated: 1:43 PM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Immunic, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Immunic to Present at the November 21st Virtual Investor Summit Microcap Event
Via ACCESSWIRE
This Yelp Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday
Via Benzinga
Peek Behind the Curtain: 7 Penny Stocks With Heavy Insider Buying
While speculative ideas are treacherous, you can possibly reduce your blood pressure with these penny stocks with insider buying. 
Via InvestorPlace
Immunic CMO discusses role of clinical trials in biotech development for Clinical Trials Day
Immunic Inc (NASDAQ:IMUX) chief medical officer Dr Andreas Muehler discusses the importance of clinical trials in the biotech industry to mark Clinical Trials Day on May 20. 
Via TheNewswire.com
Immunic CMO discusses role of clinical trials in biotech development for Clinical Trials Day
Immunic CMO discusses role of clinical trials in biotech development for Clinical Trials Day 
Via News Direct
IMUX Stock Earnings: Immunic Misses EPS for Q1 2024
IMUX stock results show that Immunic missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Immunic's Earnings Outlook
Via Benzinga
Immunic: Q3 Earnings Insights
Via Benzinga
A Preview Of Immunic's Earnings
Via Benzinga
Immunic chief medical officer discusses promising treatments to mark World IBD Day
Immunic chief medical officer discusses promising treatments to mark World IBD Day 
Via News Direct
Immunic chief medical officer discusses promising treatments to mark World IBD Day
Immunic Inc (NASDAQ:IMUX) chief medical officer Dr Andreas Muehler discusses Inflammatory Bowel Disease (IBD) with Proactive's Stephen Gunnion to mark World IBD Day on May 19. 
Via TheNewswire.com
Immunic highlights IMU-856 gastrointestinal candidate to mark International Celiac Day
Immunic highlights IMU-856 gastrointestinal candidate to mark International Celiac Day 
Via News Direct
Immunic highlights IMU-856 gastrointestinal candidate to mark International Celiac Day
Immunic Inc (NASDAQ:IMUX) chief scientific officer Hella Kohlhof joined Proactive's Stephen Gunnion on International Celiac Day, in the middle of Celiac Disease Awareness Month, to discuss the disease... 
Via TheNewswire.com
Immunic CEO Dr Daniel Vitt discusses key Q1 advances and upcoming milestones
Immunic CEO Dr Daniel Vitt discusses key Q1 advances and upcoming milestones 
Via News Direct
Topics Intellectual Property
Exposures Intellectual Property
Immunic "super excited" about latest PMS trial data
--News Direct-- 
Via News Direct
Immunic CEO Dr Daniel Vitt discusses key Q1 advances and upcoming milestones
Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt takes Proactive's Stephen Gunnion through the company's first-quarter achievements and upcoming milestones for its clinical pipeline of orally administered,... 
Via TheNewswire.com
Topics Intellectual Property
Exposures Intellectual Property
Immunic Phase 2 EMPhASIS trial data highlighted in peer-reviewed neurology journal
Immunic Phase 2 EMPhASIS trial data highlighted in peer-reviewed neurology journal 
Via News Direct
Immunic Phase 2 EMPhASIS trial data highlighted in peer-reviewed neurology journal
Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt joined Proactive's Stephen Gunnion with news of the publication of extended data from the Phase 2 EMPhASIS trial of vidofludimus calcium in... 
Via TheNewswire.com
Immunic CMO discusses complexities of multiple sclerosis to mark MS Awareness Month
--News Direct-- 
Via News Direct
Immunic CMO discusses complexities of multiple sclerosis to mark MS Awareness Month
Immunic Inc (NASDAQ:IMUX) Chief Medical Officer Dr Andreas Muehler discusses the complexities of multiple sclerosis (MS) during an interview with Proactive's Stephen Gunnion to mark MS Awareness Month,... 
Via TheNewswire.com
Immunic And 2 Other Stocks Under $2 Insiders Are Buying
The Dow Jones index closed lower by over 20 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
Exposures US Equities
What's Going On With Immunic Stock?
Immunic, Inc. (NASDAQ: IMUX) shares are roughly flat following strength early Friday after the company announced a three-tranche private placement of up to $240 million. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Pre-market stock movers are worth checking on Friday as we lay out all of the biggest stories worth keeping tabs on this morning! 
Via InvestorPlace
Immunic CSO hails "great" progress with MS program
--News Direct-- 
Via News Direct
Immunic CSO hails "great" progress with MS program
Immunic Inc (NASDAQ:IMUX) Chief Scientific Officer Hella Kohlhof speaks to Thomas Warner at the Proactive London after returning from MSMilan2023, the 9th Joint ECTRIMS-ACTRIMS meeting. She shares some... 
Via TheNewswire.com
Immunic "super excited" about latest PMS trial data
Immunic Inc (NASDAQ:IMUX) President and CEO Dr Daniel Vitt speaks to Thomas Warner from Proactive after the biotechnology company announced encouraging interim data from its phase II CALLIPER trial... 
Via TheNewswire.com
Why Startek Shares Are Trading Higher By 29%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers SuperCom Ltd. (NASDAQ: SPCB) shares jumped 89% to $0.6805, after falling 13% on Monday. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Multiple Sclerosis Impacts 1M People In US - Immunic Reveals 'Positive' Data From Nerve Disorder Candidate
Immunic Inc (NASDAQ: IMUX) announced interim data from its phase 2 CALLIPER trial of nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), in patients with  
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.